Antibody-Targeted Nanoparticles for Cancer Therapy
Authors:
- 11 March 2011
- journal article
- review article
- Published by Taylor & Francis in Immunotherapy
- Vol. 3 (3) , 381-394
Abstract
In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, in particular antibodies. Antibody-nanoparticle conjugates have the potential to elicit effective targeting and release of therapeutic targets at the disease site, while minimizing off-target side effects caused by dosing of normal tissues. This article provides an overview of various antibody-conjugated nanoparticle strategies, focusing on the rationale of cell-surface receptors targeted and their potential clinical application.Keywords
This publication has 170 references indexed in Scilit:
- Affibody-based nanoprobes for HER2-expressing cell and tumor imagingBiomaterials, 2011
- Photothermal multispectral image cytometry for quantitative histology of nanoparticles and micrometastasis in intact, stained and selectively burned tissuesCytometry Part A, 2010
- Pancreatic carcinoma cells are susceptible to noninvasive radio frequency fields after treatment with targeted gold nanoparticlesSurgery, 2010
- The Complex Role of Multivalency in Nanoparticles Targeting the Transferrin Receptor for Cancer TherapiesJournal of the American Chemical Society, 2010
- Photoacoustic imaging of living mouse brain vasculature using hollow gold nanospheresBiomaterials, 2010
- Effects of nanomaterial physicochemical properties on in vivo toxicityAdvanced Drug Delivery Reviews, 2009
- HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitorsCancer Treatment Reviews, 2009
- Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptideInternational Journal of Pharmaceutics, 2009
- Tumor-specific antibody-mediated targeted delivery of Doxil® reduces the manifestation of auricular erythema side effect in miceInternational Journal of Pharmaceutics, 2008
- shRNA and siRNA delivery to the brainAdvanced Drug Delivery Reviews, 2007